Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Core R&D: -$10,295M in FY2025, up 10.7% from a year earlier. That is the lowest of the 9 years on record here.
Latest, FY2025
-10,295
Period ended Dec 31, 2025
Change on a year earlier
+10.7%
-9,302 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below
Where the FY2025 figure comes from
“|| Research and development | -11 200 | 392 | 491 | 16 | 6 | -10 295 | -9 302”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core R&D ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -10,295 | +10.7% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | -9,302 | +1,307.3% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | -661 | -19.5% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | -821 | -7.9% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | -891 | +5.1% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | -848 | +523.5% | Novartis Form 6-K (0001370368-22-000009) ↗ |
| FY2019 | Dec 31, 2019 | -136 | -74.2% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | -527 | +4.4% | Novartis Form 6-K (0001370368-19-000006) ↗ |
| FY2017 | Dec 31, 2017 | -505 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Cite this data
StockData. (2026). Novartis Core R&D ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/core-rd
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.